A study showing that deep-brain stimulation helped treat patients with Parkinson's disease could prove to be a boon for Medtronic Inc.'s growing neuromodulation business.
By Thomas Lee
The conclusions from a major study on deep-brain stimulation published in the New England Journal of Medicine today seemed rather anti-climatic, at least on the surface.
There was no real difference between implanting a DBS device in the globus pallidus interna and subthalamic nucleus regions of the brains in patients suffering from Parkinson’s disease. Each worked equally as well.
But for Medtronic Inc. (NYSE:MDT), which funded the study, the results are signficant because it gives doctors more flexibility (and clinical comfort) in using its Activa PC and RC devices, the first and only DBS devices approved by the Food & Drug Administration to treat movement disorders in the United States.
And greater flexibility means a greater pool of potential patients.
Medtronic’s neurostimulation sales in fiscal 2010 rose 9 percent to $1.6 billion, driven largely by Activa sales.
Doctors tend to target the SN region for DBS therapy, even though there’s no evidence that that location produces better results than the GPI. Researchers randomly implanted Medtronic devices in either region in 300 patients across the country and compared the results.
(The U.S. Dept. of Veteran Affairs, the National Institute of Neurological Disorders and Stroke, and Medtronic paid for the study. The study insisted Medtronic had no role in designing the study or interpreting the results, although several of the authors have received grants, lecturing and consulting fees from the company.)
After 26 months, patients in both groups reported significant improvement in motor control, the primary objective of the study, as measured by the Unified Parkinson’s Disease Rating Scale. The scale measures motor control in areas such as speech, facial expression and hand tremors on a zero-to-four-point scale, with zero denoting no symptoms or normal function and four indicating severe symptoms or interference in function.
Overall, the GPI group reported a 11.8-point reduction; SN patients boasted a 10.7 point decline.
NeuWave Medical raised more than $25 million in equity financing as it works to advance the market...
ConforMIS files for an initial public offering worth up to $173 million for its customized joint...
Here's a look at some of the top legal news stories for medical device companies this week: PAD:...
Mind-controlled prosthetics allow quadriplegic Erik Sorto to drink his 1st beer in a decade by...